Instil Bio Q2 2024 Earnings Report

Instil Bio EPS Results

• Actual EPS: -$2.29
• Consensus EPS: -$2.98
• Beat/Miss: Beat by +$0.69
• One Year Ago EPS: N/A

Instil Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Instil Bio Announcement Details

• Quarter: Q2 2024
• Date: 8/13/2024
• Time: TAS
• Conference Call Date: N/A
• Conference Call Time: N/A

Instil Bio (NASDAQ:TIL) plc is a clinical‐stage biotechnology company focused on the discovery, development and delivery of off‐the‐shelf cell therapies for cancer and other serious diseases. The company’s proprietary Instinct Platform leverages high‐parameter single‐cell multiomics, machine learning and immunological screening to identify and engineer natural killer (NK) and T cell products with enhanced potency, persistence and safety. Instil Bio’s technology backbone is designed to accelerate the translation of novel cellular candidates through in vitro and in vivo models, providing a systematic approach to next‐generation immuno‐oncology therapies.

The company’s pipeline includes lead programs such as INB‐101, an allogeneic, engineered NK cell therapy currently in Phase 1 clinical evaluation for refractory solid tumors, and a series of follow‐on candidates collectively known as the INB‐200 series. These programs employ targeted genetic modifications to improve tumor antigen recognition, enhance cell trafficking and resist the immunosuppressive tumor microenvironment. Beyond oncology, Instil Bio is exploring applications in rare hematological disorders and infectious diseases by adapting its platform to different immune cell types and therapeutic modalities.

Founded in 2020 and headquartered in the United Kingdom and United States, Instil Bio combines multidisciplinary expertise in immunology, genomics and cell therapy manufacturing. The company completed its Nasdaq listing via a business combination in 2022, positioning it to advance multiple clinical programs while expanding its research and manufacturing capabilities. Led by a management team with deep experience in biotech R&D and commercialization, Instil Bio aims to establish a new standard for the discovery and development of engineered cell therapies on a global scale.